 |
|
|
| |
Safety, Pharmacokinetics, and Efficacy of FTC/TAF in HIV-Infected Adolescents (12-18 years)
|
| |
| |
Reported by Jules Levin
CROI 2018 March 4-7 Boston MA
Janet S. Chen,1 Xavier Saez-Llorens,2 Elizabeth Castano,2 Feezah Patel,3 Ann Melvin,4 Elizabeth J. McFarland,5 Jaime G. Deville,6 Mark Cotton,7
Chrisna Andersen,8 Heather Maxwell,9 Mingjin Yan,9 Sophia R. Majeed,9 Erin Quirk,9 Hiba Graham,9 Cheryl Pikora9
1Drexel University College of Medicine, Philadelphia, PA; 2Hospital del Nino, Panama City, Panama; 3Empilweni Services and Research Unit, Johannesburg, South Africa; 4Seattle Children's Hospital, Seattle, WA; 5University of Colorado Anschutz Medical Campus
and Children's Hospital Colorado, Aurora, CO; 6David Geffen School of Medicine at UCLA, Los Angeles, CA; 7Tygerberg Hospital, Capetown, South Africa; 8Be Part Yoluntu Centre, Paarl, South Africa; 9 Gilead Sciences, Inc., Foster City, CA
References
1. AIDSinfo. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf;
2. Lawson EB, et al. ICAAC 2014, poster H-1012;
3. Descovy [SmPC]. Foster City, CA: Gilead Sciences,
Inc., Oct 2017;
4. Descovy [package insert]. Foster City, CA: Gilead Sciences, Inc., Sep 2017;
5. Gaur A, et al. Lancet HIV 2016;3:e561-8;
6. Natukunda E, et al. Lancet Child Adol Health
2017;1:27-34;
7. Genvoya [package insert]. Foster City, CA: Gilead Sciences, Inc., Nov 2017; 8. CDC.
http://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/index.htm.
|
| |
|
|
|
|
|
